KYMERA THERAPEUTICS, INC. Number of Reportable Segments
KYMERA THERAPEUTICS, INC. (KYMR) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- KYMERA THERAPEUTICS, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month |
|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-11 | ||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |